[The fundamental and clinical studies on PT-122M (doxycycline) in the otorhinolaryngological field (author's transl)].
As the results of laboratory and clinical investigation with a new tetracycline derivate, PT-122M (doxycycline) was performed with the results which may lead to the following conclusions. 1) In vitro antibacterial activity: The minimal inhibitory concentration of doxycycline (DOTC) was measured by an agar plate dilution method. The MIC of DOTC against 60 strains of coagulase-positive Staphylococcus aureus isolated from otorrhoea was distributed over a range of 0.2 approximately 1.56 mcg/ml and 12.5 approximately 50 mcg/ml. Furthermore, Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae was 3.13 to 100 mcg/ml. 2) Concentration in blood: The blood level of DOTC in healthy adults who were given 100 mg of DOTC intravenous reached maximum of 1.97 mcg/ml on the average 15 minutes after injection. Even at 12 hours after intravenous injection clinically effective serum DOTC concentration of 0.47 mcg/ml was still demonstrable. 3) CLINICAL RESULTS: PT-122M (DOCT) was intravenously injected into 30 cases with typical infection in the field of otorhinolaryngology. It was excellent in 15 cases, good in 10 cases, fair in 3 cases, and poor in 2 cases. When the cases in which it was excellent and good were considered together, good results were obtained in 25 cases, a ratio of effectiveness being 83 per cent. 4) Side effect: The comparative examination of hepatic function, electrolyte and auditory acuity before and after injection showed no significant disturbance. No side effect was shown with the intravenous injection.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D004318:Doxycycline / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D005667:Furunculosis / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008297:Male; D008443:Maxillary Sinus; D008875:Middle Aged; D010033:Otitis Media / Q000188:drug therapy / Q000382:microbiology; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D011513:Proteus mirabilis / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012852:Sinusitis / Q000188:drug therapy / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification; D014069:Tonsillitis / Q000188:drug therapy
D004318:Doxycycline